Ironwood Pharmaceuticals Inc. (IRWD)
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Shares Tank on Regulatory Update for Apraglutide
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZESS remains the market leader, and Ironwood's restructuring efforts aim to streamline operations and focus on apraglutide. Apraglutide's strong clinical data and potential FDA approval could significantly boost Ironwood's revenue, positioning it as a key player in the SBS market.
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Jason Butler - Citizens JMP Matt Cowper - Leerink Partners David Amsellem - Piper Sandler Operator My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Fourth Quarter 2024 Investor Update Conference Call.
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to break-even earnings per share a year ago.
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in the Inflation Reduction Act that aims to make costly medications more affordable for seniors.
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024.
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Conference Call Participants Amy Li - Jefferies David Amsellem - Piper Sandler Jason Butler - Citizens JMP Mohit Bansal - Wells Fargo Operator Thank you for standing by. My name is Louella, and I will be your conference operator today.
